A Serology-Based Approach Combined With Clinical Examination of 125 Ro/SSA-Positive Patients to Define Incidence and Prevalence of Subacute Cutaneous Lupus Erythematosus

2008 ◽  
Vol 2008 ◽  
pp. 213-214
Author(s):  
B.H. Thiers
Keyword(s):  
Clinical Examination ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Subacute Cutaneous Lupus Erythematosus ◽  
Cutaneous Lupus

scholarly journals Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine

2021 ◽  
Author(s):  
Dennis Niebel ◽  
Veronika Ralser‐Isselstein ◽  
Kristel Jaschke ◽  
Christine Braegelmann ◽  
Thomas Bieber ◽  
...  
Keyword(s):  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Subacute Cutaneous Lupus Erythematosus ◽  
Cutaneous Lupus

scholarly journals A Case of Subacute Cutaneous Lupus Erythematosus in a Patient with Mixed Connective Tissue Disease: Successful Treatment with Plasmapheresis and Rituximab

2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
M. Fantò ◽  
S. Salemi ◽  
F. Socciarelli ◽  
A. Bartolazzi ◽  
G. A. Natale ◽  
...  
Keyword(s):  
Connective Tissue ◽  
Connective Tissue Disease ◽  
Lupus Erythematosus ◽  
Mixed Connective Tissue Disease ◽  
High Titer ◽  
Cutaneous Lupus Erythematosus ◽  
Subacute Cutaneous Lupus Erythematosus ◽  
Anti Cd20 ◽  
Skin Healing ◽  
Cutaneous Lupus

A 30-year-old woman affected by Mixed Connective Tissue Disease with scleroderma spectrum developed a facial eruption, a clinical and histological characteristic of subacute cutaneous lupus erythematosus (SCLE). Speckled anti-nuclear antibodies, high-titer anti-ribonucleoprotein1, anti-Sm, anti-Cardiolipin (aCL) IgG/IgM, and anti-Ro/SSA antibodies were positive. SCLE was resistant to Azathioprine, Hydroxychloroquine, and Methotrexate while Mycophenolate Mofetil was suspended due to side effects. Subsequently, the patient was treated with three cycles of therapeutic plasma exchange (TPE) followed, one month after the last TPE, by the anti-CD20 antibody Rituximab (RTX) (375 mg/m2weekly for 4 weeks). Eight and 16 months later the patient received other two TPE and RTX cycles, respectively. This therapeutic approach has allowed to obtain a complete skin healing persistent even after 8-month follow-up. Moreover, mitigation of Raynaud's phenomenon, resolution of alopecia, and a decline of aCL IgG/IgM and anti-Ro/SSA antibodies were observed.

Sign in / Sign up

Export Citation Format

Share Document